[1] |
MURTHY S E, CHATTERJEE F, CROOK A, et al. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis[J]. BMC Med, 2018, 16(1):73.
DOI
URL
|
[2] |
LAI S W, LIN C L, LIAO K F. Association between pulmonary tuberculosis and acid suppressive agents[J]. Postgrad Med J, 2020, 96(1133):165.
DOI
URL
|
[3] |
RICHTERMAN A, STEER-MASSARO J, JAROLIMOVA J, et al. Cash interventions to improve clinical outcomes for pulmonary tuberculosis:systematic review and meta-analysis[J]. Bull World Health Organ, 2018, 96(7):471-483.
DOI
URL
|
[4] |
DABLOOL. Surveillance of one-year pulmonary tuberculosis cases at Al Taif province using different diagnostic tools[J]. Life Sciences, 2019, 16(3):27-32.
|
[5] |
YUSTE J R, SERRANO-ALONSO M, CARMONA-TORRE F, et al. Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis[J]. J Antimicrob Chemother, 2019, 74(9):2817-2819.
DOI
URL
|
[6] |
SAAD J, BARON S, LAGIER J C, et al. Mycobacterium bovis pulmonary tuberculosis after ritual sheep sacrifice in Tunisia[J]. Emerg Infect Dis, 2020, 26(7):1605-1607.
DOI
URL
|
[7] |
张永强, 刘兰瑞, 张雁, 等. XpertMTB/RIF技术对结核病以及耐药结核病的诊断应用价值[J]. 中国实验诊断学, 2018, 22(4):654-655.
|
[8] |
肺结核诊断WS 288—2017[J]. 中国感染控制杂志, 2018, 17(7):642-652.
|
[9] |
CONRADIE F, DIACON A H, NGUBANE N, et al. Treatment of highly drug-resistant pulmonary tuberculosis[J]. N Engl J Med, 2020, 382(10):893-902.
DOI
URL
|
[10] |
SHUAIB Y A, KHALIL E A G, WIELER L H, et al. Mycobacterium tuberculosis complex lineage 3 as causative agent of pulmonary tuberculosis,Eastern Sudan[J]. Emerg Infect Dis, 2020, 26(3):427-436.
DOI
URL
|
[11] |
CAMPRUBÍ D, GOMILA A, GRIJOTA-CAMINO M D, et al. Infectiousness of patients with smear-negative pulmonary tuberculosis,assessed by real-time polymerase chain reaction,Xpert® MTB/RIF[J]. J Infect, 2020, 80(3):298-300.
DOI
URL
|
[12] |
吴小翠, 余方友. 结核病实验室诊断的进展及挑战[J]. 中华传染病杂志, 2021, 39(10):591-597.
|
[13] |
ZAR H J, NICOL M P. Strengthening diagnosis of pulmonary tuberculosis in children:the role of Xpert MTB/RIF ultra[J]. Pediatrics, 2019, 144(5):e20192944.
DOI
URL
|
[14] |
郭志峰. 血清中期因子、血小板因子4和黏蛋白1含量检测对乳腺癌患者病情评估的价值[J]. 中国医药导报, 2017, 14(11):99-102.
|
[15] |
李榜龙, 鲁学明, 周外民. 贞芪扶正颗粒对肺结核化疗患者免疫功能及炎症因子的影响[J]. 中国煤炭工业医学杂志, 2018, 21(5):463-467.
|
[16] |
余艳艳, 谭云洪, 朱权, 等. INF-γ和IL-2联合检测在结核病辅助诊断中的价值[J]. 检验医学与临床, 2019, 16(11):1477-1479.
|
[17] |
林永通, 麦世康. GeneXpert Mtb/RIF检测技术在结核病诊断中的应用评价[J]. 中国热带医学, 2018, 18(1):93-95.
|
[18] |
熊梦园, 方芳, 李一荣. Xpert MTB/RIF检测技术对肺结核的诊断价值[J]. 海南医学, 2020, 31(5):554-558.
|
[19] |
廖彥, 林翀, 林明冠, 等. 血清基质金属蛋白酶-9在肺结核鉴别诊断中的价值分析[J]. 中国免疫学杂志, 2018, 34(10):1542-1546.
|
[20] |
王浩, 徐叶红, 郝建, 等. TB-IGRA对肺结核的诊断价值及假阴性影响因素探讨[J]. 临床肺科杂志, 2018, 23(7):1190-1193.
|